Maat Pharma (XPAR:MAAT) Total Debt per Share: €0.82 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:MAAT Maat Pharma SA XPAR:MAAT
29 GF Score
Price €2.96
GF Value €10.83
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Maat Pharma Total Debt per Share?

Maat Pharma XPAR:MAAT -2.15% 29 Total Debt per Share is €0.82 as of Dec. 2025. GuruFocus rates XPAR:MAAT with a GF Score™ of 29/100 and a GF Value™ of €10.83 (Possible Value Trap). The stock has 3 warning signs investors should review.

€0.82 (As of Dec. 2025)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Maat Pharma's Total Debt Per Share for the quarter that ended in Dec. 2025 was €0.82.

Maat Pharma Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Maat Pharma's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maat Pharma Total Debt per Share Chart

Maat Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial 0.59 1.14 1.21 1.14 0.82

Maat Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 1.24 1.14 0.89 0.82
XPAR:MAAT
29GF Score
Maat Pharma SA XPAR:MAAT
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maat Pharma Total Debt per Share Calculation

Maat Pharma's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(12.91+2.49)/18.82
=0.82

Maat Pharma's Total Debt Per Share for the quarter that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(12.91+2.49)/18.82
=0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of €0.82 mean?
Maat Pharma (XPAR:MAAT) has a Total Debt per Share of €0.82 as of Dec. 2025. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Maat Pharma and its competitors.
Is Maat Pharma's Total Debt per Share too high?
Maat Pharma's current Total Debt per Share is €0.82. Overall, Maat Pharma has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Maat Pharma's Total Debt per Share compare to VRTX and REGN?
Maat Pharma's Total Debt per Share of €0.82 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Maat Pharma and its competitors. Maat Pharma's current Total Debt per Share is €0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Maat Pharma (XPAR:MAAT) is currently considered Possible Value Trap. The stock's GF Value™ is €10.83, compared to a current price of €2.96 — trading 72.7% below its estimated fair value. The current Total Debt per Share is €0.82. Maat Pharma's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Maat Pharma (XPAR:MAAT), the current Total Debt per Share is €0.82 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maat Pharma (XPAR:MAAT) Overvalued in 2026?

Based on GuruFocus' analysis, Maat Pharma stock appears to be undervalued. The current stock price of €2.96 is trading 72.7% below its estimated GF Value™ of €10.83. GuruFocus considers Maat Pharma to be Possible Value Trap.

Key valuation signals for XPAR:MAAT:

  • Total Debt per Share: €0.82
  • GF Value™: €10.83 vs. price of €2.96 (72.7% below fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the XPAR:MAAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Maat Pharma Business Description

Other Exchanges 4RD:Germany
Address 70 Avenue Tony Garnier, Lyon, FRA, 69007
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
29GF Score

Get the complete analysis for XPAR:MAAT

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.96
Price
€10.83
GF Value